【2022年1月締切】CiNii ArticlesへのCiNii Researchへの統合に伴う機関認証の移行確認について

【1/6更新】2022年4月1日からのCiNii ArticlesのCiNii Researchへの統合について

Susceptibility of Methicillin-resistant Staphylococcus aureus Clinical Isolates to Various Antimicrobial Agents. IV. Aminoglycoside-modifying Enzyme AAC(6')/APH(2") is Responsible for Arbekacin-resistance Enhanced by Bleomycin

この論文をさがす

抄録

type:text

Resistance patterns against various antimicrobial agents including β-lactams, aminoglycosides, tetracyclines, fluoroquinolones, macrolides were examined for 58 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated at Hiroshima University Hospital from April to November 1992. All the MRSA strains produced type II-coagulase but notβ-lactamase.   Regarding aminoglycoside-modifying enzymes, 7 strains (12%) appeared to be producing aminoglycoside 4',4"-adenyltransferase AAD(4',4") encoded by aadD without coproduction of bifunctional aminoglycoside 6' -acetyltransferase/2" -phosphotransferase AAC(6')/APH(2") encoded by aacA-aphD (referred to as tobramycin-resistant type, TOBr). The remaining 51 strains (88%) were phenotypically producers of both enzymes (i.e., mix-resistant type, Mixr). AAD(4',4"), encoded by aadD which was reported to be closely linked with bleomycin (BLM)-resistance determinant, could be seen in 100% MRSA strains and ca. 90% strains expressed AAC(6')/APH(2"). BLM endowed Mixr-type but not TOBr-type MRSA strain with enhanced resistance to arbekacin (ABK) dose-dependently, presumably by modifying the production of AAC(6')/APH(2"). The manifestation of ABK-resistant phenotype by Mixr-type MRSA required the coexistence of BLM. Therefore, ABK must be administered carefully to cure MRSA infection in patients who have been treated with BLM.

収録刊行物

被引用文献 (0)*注記

もっと見る

参考文献 (0)*注記

もっと見る

関連論文

もっと見る

関連研究データ

もっと見る

関連図書・雑誌

もっと見る

関連博士論文

もっと見る

関連プロジェクト

もっと見る

関連その他成果物

もっと見る

詳細情報

ページトップへ